Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)

(2016) Kelly E. Caudle et al.   GENETICS IN MEDICINE

CYP450 genotyping and cumulative drug–gene interactions: an update for precision medicine

(2016) Ranjit K Thirumaran et al.   Personalized Medicine

Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing

(2015) B. T. Hocum et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation toCYP2C19andCYP3A5genotypes

(2015) Ho-Sook Kim et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2D6andCYP2C19Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

(2015) JK Hicks et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study

(2015) Aizati N. A. Daud et al.   DRUG SAFETY

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole

(2015) Chiyo K. Imamura et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Interaction between sulthiame and clobazam: Sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19

(2014) Yoshiaki Yamamoto et al.   EPILEPSY & BEHAVIOR

Understanding adverse drug reactions in older adults through drug–drug interactions

(2014) A. Marengoni et al.   European Journal of Internal Medicine

How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping

(2014) Paul Verbeurgt et al.   PHARMACOGENOMICS

Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction

(2014) J P Depta et al.   PHARMACOGENOMICS JOURNAL

The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes

(2014) Fen Jiang et al.   PSYCHOPHARMACOLOGY

Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity

(2014) Yassine Bouatou et al.   AIDS Research and Therapy

Understanding and preventing drug–drug and drug–gene interactions

(2014) Cara Tannenbaum et al.   Expert Review of Clinical Pharmacology

Impact of Genetic Polymorphism on Drug-Drug Interactions Mediated by Cytochromes: A General Approach

(2013) Michel Tod et al.   AAPS Journal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

PP134—Esomeprazole used as a booster in a HIV ultrarapid CYP2C19 metabolizer treated with voriconazole

(2013) Y. Bouatou et al.   CLINICAL THERAPEUTICS

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent

(2013) V Michaud et al.   PHARMACOGENOMICS JOURNAL

Influence of CYP2C19 Polymorphism and Concomitant Antiepileptic Drugs on Serum Clobazam and N-Desmethyl Clobazam Concentrations in Patients With Epilepsy

(2013) Yoshiaki Yamamoto et al.   THERAPEUTIC DRUG MONITORING

Severe Tremor After Cotrimoxazole-Induced Elevation of Venlafaxine Serum Concentrations in a Patient With Major Depressive Disorder

(2013) Christian Geber et al.   THERAPEUTIC DRUG MONITORING

Importance of Multi-P450 Inhibition in Drug–Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data

(2012) Nina Isoherranen et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Induction of CYP2C19 and CYP3A Activity Following Repeated Administration of Efavirenz in Healthy Volunteers

(2012) V Michaud et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Influence of Omeprazole on Platelet Inhibition of Clopidogrel in Various CYP2C19 Mutant Alleles

(2012) Qian Liu et al.   Genetic Testing and Molecular Biomarkers

Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents

(2012) Y. Fujita et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

A Thorough QTc Study of 3 Doses of Iloperidone Including Metabolic Inhibition Via CYP2D6 and/or CYP3A4 and a Comparison to Quetiapine and Ziprasidone

(2012) Steven G. Potkin et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population

(2012) Ameet Bakhai et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis

(2012) Ana Miguel et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

A clinically significant interaction between warfarin and simvastatin is unique to carriers of theCYP2C9*3allele

(2012) Marine L Andersson et al.   PHARMACOGENOMICS

Pharmacogenetic Determinant of the Drug Interaction Between Tacrolimus and Omeprazole

(2012) Wei Zhao et al.   THERAPEUTIC DRUG MONITORING

Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug–drug interaction

(2012) Srecko Marusic et al.   International Journal of Clinical Pharmacy

Detection and Prevention of Drug–Drug Interactions in the Hospitalized Elderly: Utility of New Cytochrome P450–Based Software

(2011) Hubert Zakrzewski-Jakubiak et al.   American Journal Geriatric Pharmacotherapy

Potentially Harmful Drug–Drug Interactions in the Elderly: A Review

(2011) Lisa E. Hines et al.   American Journal Geriatric Pharmacotherapy

Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment

(2011) Thomas M. Polasek et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

(2011) J A Johnson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

(2011) J J Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine

(2011) Junichi Azuma et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes

(2010) Takahisa Furuta et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Inhibition of Cytochrome P450 Enzymes 2D6 and 3A4 on the Pharmacokinetics of Intravenous Oxycodone

(2010) Juha Grönlund et al.   CLINICAL DRUG INVESTIGATION

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

(2010) B C Goh et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Changes in the QTc interval after administration of flecainide acetate, with and without coadministered Paroxetine, in Relation to Cytochrome P450 2D6 Genotype: Data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects

(2010) Kyoung Soo Lim et al.   CLINICAL THERAPEUTICS

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism

(2010) Hui-Yan Shi et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Fatal Hydrocodone Overdose in a Child: Pharmacogenetics and Drug Interactions

(2010) P. Madadi et al.   PEDIATRICS

Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes

(2010) J.-H. Tu et al.   XENOBIOTICA

Gefitinib-phenytoin interaction is not correlated with the14C-erythromycin breath test in healthy male volunteers

(2009) Stephanie Chhun et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers

(2009) SV Vormfelde et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Impact of Intestinal CYP2C19 Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant Patients

(2009) K. Hosohata et al.   DRUG METABOLISM AND DISPOSITION

Polymorphism of human cytochrome P450 enzymes and its clinical impact

(2009) Shu-Feng Zhou et al.   DRUG METABOLISM REVIEWS

O-demethylation of codeine to morphine inhibited by low-dose levomepromazine

(2009) M. Vevelstad et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of drug–drug interactions with fesoterodine

(2009) Bimal Malhotra et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Clopidogrel Inhibits CYP2C19-Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms

(2009) B. L. Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Toward Optimal Treatment in Women: The Effect of Sex on Metoprolol-Diphenhydramine Interaction

(2009) Ashish Sharma et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia

(2008) Yanfeng Wang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Differential Genotype Dependent Inhibition of CYP2C9 in Humans

(2008) V. Kumar et al.   DRUG METABOLISM AND DISPOSITION

Interaction between Tacrolimus and Lansoprazole, but not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5

(2008) Keiko Hosohata et al.   Drug Metabolism and Pharmacokinetics

The Role of Cytochrome P2C19 in R-warfarin Pharmacokinetics and its Interaction With Omeprazole

(2008) Tsukasa Uno et al.   THERAPEUTIC DRUG MONITORING